IHS Chemical Week

EnviroTech :: Regulatory

New U.S. Biosimilars Bill Gets Mixed Reviews

10:26 AM MDT | April 7, 2008 | Deepti Ramesh

A new House bill on biosimilars is drawing mixed reviews from industry. The Generic Pharmaceutical Association (GPhA; Arlington, VA) calls the Pathway for Biologics Act “a step backward” that puts brand company profits before patient needs, but the Biotechnology Industry Organization (BIO; Washington) says the bill is an important step forward toward follow-on biologics. Representatives Anna Eshoo (D., CA) and Joe Barton (R., TX) introduced the bill last month. Eshoo: Pathway to promote innovation. The bill provides 12 years of data exclusivity for...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa